Welcome to our dedicated page for Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) is at the forefront of developing innovative respiratory support technology as an alternative to invasive mechanical ventilation. The company's flagship product, INSPIRA ART100, is a breakthrough in Augmented Respiration Technology designed to maintain optimal oxygen levels in patients without the need for intubation and sedation. This technology is particularly significant in the treatment of respiratory failure and offers a less invasive option compared to traditional mechanical ventilation.
Inspira Technologies operates in various regions, including North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The company is involved in the research, development, manufacture, and marketing of proprietary respiratory care devices, aiming to transform the landscape of acute and neonatal care.
Recently, Inspira Technologies has announced several key developments:
- April 3, 2024: Commencement of a program to explore the use of the INSPIRA ART100 Device for an artificial womb for neonates requiring vital respiratory support.
- April 10, 2024: Collaborative development with Ennocure MedTech Ltd. on bio-electronic treatment to prevent bloodstream infections in ICU patients, showcasing a 100% reduction in bacterial growth within 24 hours in an in vitro study.
- April 16, 2024: Signing of a collaboration term sheet with Beilinson Hospital for the evaluation of the INSPIRA ART100 device in organ transplant procedures.
- April 25, 2024: Receiving CSA Certification of Compliance to U.S. standards for the INSPIRA ART100 device.
- May 2, 2024: Initiation of the production of the INSPIRA ART100 medical device by a leading technology company.
- May 28, 2024: Notification of 510(k) class II clearance from the U.S. FDA for the INSPIRA ART100.
Inspira's products are designed not only to enhance patient outcomes but also to reduce the costs and complications associated with traditional respiratory support methods. The INSPIRA ART100 system has received FDA clearance, marking a pivotal moment in the company's history. Other products in the pipeline, including the INSPIRA ART (Gen 2) and HYLA™ blood sensor, are poised to further revolutionize respiratory care once approved.
Inspira Technologies has submitted a patent application for a new supportive device aimed at improving treatment and mobility for cannulated patients, enhancing procedures for medical staff. This device is designed to assist patients requiring Extracorporeal Membrane Oxygenation (ECMO) and other treatments such as COVID-19, COPD, and ARDS. CEO Dagi Ben-Noon emphasized its potential impact on patient outcomes and rapid patent acquisition through the Israeli Patent Office, recognized for its efficiency. The ART device, functioning as an 'artificial lung,' remains untested in humans and lacks FDA approval.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has announced participation in two upcoming virtual conferences. Joe Hayon, Co-Founder and CFO, will be featured at the H.C. Wainwright 23rd Annual Global Investment Conference with an on-demand presentation available from September 13, 2021. He will also present at the Benzinga Small/Mid Cap Healthcare Conference on September 29, 2021, at 10:50 am ET. The company specializes in proprietary respiratory support technologies designed to stabilize patient oxygen levels without invasive mechanical ventilation.
Inspira Technologies OXY B.H.N. Ltd (Nasdaq: IINN) announced the successful completion of a pump bench study for its ART device, aimed at providing extracorporeal respiratory support. This milestone allows the company to advance towards the manufacturing phase of the ART device, designed to function as an "external lung" and enable patients to remain awake during treatment. The study compared Inspira's pump with leading centrifugal pumps, emphasizing its potential to minimize blood damage. However, the ART device has not yet undergone human testing or received FDA approval.
Inspira Technologies OXY B.H.N. Ltd (Nasdaq: IINN) reported financial results for the six months ending June 30, 2021. The company raised $16 million through its IPO and has $4.36 million in cash. R&D expenses decreased to $1.10 million, while marketing expenses were $244,000. The net loss increased to $8.29 million compared to $4.35 million in 2020, attributed to higher finance expenses. The company aims to target a $25 billion market with its Augmented Respiration Technology (ART) and plans to double its workforce to support development efforts.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has appointed Lior Amit, CPA, to its board of directors to enhance its market strategy, particularly for the Augmented Respiration Technology (ART) system. Amit brings over 17 years of CFO experience from BBR Saatchi & Saatchi and currently serves on the boards of multiple start-ups. The ART technology aims to provide cost-effective respiratory treatment while patients are awake, potentially reducing reliance on invasive mechanical ventilation. However, the product has yet to undergo human testing or receive FDA approval.
Inspira Technologies Oxy B.H.N. Ltd. (IINN) has appointed Dr. Dekel Stavi to its Medical Advisory Board, enhancing its strategic expansion into North America. Dr. Stavi brings extensive experience in intensive care medicine and leadership in Extracorporeal Life Support programs. His role is expected to significantly contribute to the introduction of Inspira's innovative respiratory technology, which aims to improve oxygen saturation levels in patients. However, the company's products are not yet FDA-approved and have not been tested in humans.
Aegis Capital Corp. acted as Sole Bookrunner for a $16.0 million Initial Public Offering of Common Units for Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW). The company is focused on respiratory treatments with its innovative Augmented Respiration Technology that stabilizes oxygen saturation levels, allowing patients to remain awake during treatment.
This technology aims to reduce reliance on mechanical ventilation, which is often invasive and risky.
Inspira Technologies, a leader in respiratory medical technology, announced a significant development in preventing blood clotting with its Augmented Respiration Technology (ART) system. Collaborating with Ben-Gurion University, the company aims to enhance the ART system by integrating a platform that utilizes polymeric microbubbles to release oxygen on demand. This innovation seeks to improve patient outcomes by potentially eliminating the need for anticoagulants, which carry risks of life-threatening bleeding. The ART system, still in development, aims to stabilize patient oxygen levels without mechanical ventilation.
Inspira Technologies OXY B.H.N. Ltd has successfully closed its initial public offering (IPO) of 2,909,091 units at a price of $5.51 per unit, generating approximately $16 million in gross proceeds. Each unit includes one ordinary share and one warrant. The company has granted Aegis Capital Corp. a 45-day option for additional shares and warrants. The shares and warrants are now trading on Nasdaq under symbols IINN and IINNW respectively. Notably, Inspira's Augmented Respiration Technology is still pending FDA approval and human testing.
Inspira Technologies OXY B.H.N. Ltd announced the pricing of its initial public offering (IPO) of 2,909,091 common units, priced at $5.51 each, comprising one ordinary share and one warrant per unit. The offering is expected to raise $16 million in gross proceeds and is set to close on July 16, 2021, subject to customary conditions. Additionally, Aegis Capital Corp. has a 45-day option to purchase up to 15% more common units to cover over-allotments. Trading on Nasdaq is expected to begin on July 14, 2021 under the symbols IINN and IINNW.
FAQ
What is the current stock price of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)?
What is the market cap of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)?
What does Inspira Technologies do?
What is the INSPIRA ART100?
What regions does Inspira Technologies operate in?
What recent programs has Inspira Technologies announced?
Who are some of Inspira Technologies' partners?
Has the INSPIRA ART100 received regulatory approval?
What makes the INSPIRA ART100 different from traditional mechanical ventilation?
What is the significance of the CSA Certification of Compliance?
What is the financial impact of mechanical ventilation in the U.S.?
Where can I find more information about Inspira Technologies?
